Investigation of the pharmacological activity of the tetrapeptide HAEЕ, zinc, and human serum albumin in a transgenic mouse model with tau protein overexpression (P301S)

Introduction: Neurodegenerative diseases affecting neurons represent a wide spectrum of pathological conditions. To slow the accumulation of pathological tau protein, therapeutic interventions such as a pharmaceutical composition consisting of the tetrapeptide HAEЕ, zinc, and albumin may be employed. This composition possesses properties that can potentially slow disease progression. Materials and Methods: The experiment was performed on 60 homozygous mice of both sexes from a transgenic line with the overexpression of human mutant tau protein (P301S) and on 20 mice from a wild-type C57Bl/6J background line. Control groups (C57Bl/6J – K and P301S – K+) received NaCl injection water (100 µL subcutaneously, once every 2 days); the experimental group (P301S) received HAEE-Zn-HSA (75 mg/kg, 150 µL subcutaneously, once every 2 days); and the comparison group (P301S) received piracetam (1.75 g/kg, 175 µL subcutaneously, once every 2 days). Behavioral activity was analyzed using tests at two time points, and the phenotypic presentation and lifespan were evaluated. Results and Discussion: The P301S group of mice treated with HAEE-Zn-HSA at a dosage of 75 mg/kg showed positive behavioral activity in the following tests: Open Field, Novel Object Recognition, and Inverted grid test, indicating increased exploratory activity, and improved motor function and coordination in the mice of this group. Pharmacological intervention with HAEE-Zn-HSA in the experimental group of transgenic mice demonstrated positive results, as a statistically significant effect on lifespan and delayed onset of the phenotypic presentation of the disease was shown (24±2.14 weeks, p≤0.05). Conclusion: The pharmaceutical composition HAEE-Zn-HSA at a dosage of 75 mg/kg, using a model of homozygous mice from a transgenic line with overexpression of human mutant tau protein P301S, demonstrated high levels of adaptive and exploratory activity and improved motor function.

Authors

Institutions

Publication Details

Journal
Research Results in Pharmacology
Published
2025-03-28
DOI
https://doi.org/10.18413/rrpharmacology.11.493
Citations
2
Primary Topic
Chemical Synthesis and Analysis
Type
article
Field-Weighted Citation Impact
1.61
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Investigation of the pharmacological activity of the tetrapeptide HAEЕ, zinc, and human serum albumin in a transgenic mouse model with tau protein overexpression (P301S)

Yulia V. Stepenko, Tatyana V. Avtina, Вероника С. Шмигерова, Никита С. Жунусов et al.
2 citations
Research Results in Pharmacology
Chemical Synthesis and Analysis
1.61
article

Investigation of the pharmacological activity of the tetrapeptide HAEЕ, zinc, and human serum albumin in a transgenic mouse model with tau protein overexpression (P301S)

Yulia V. Stepenko, Tatyana V. Avtina, Вероника С. Шмигерова, Никита С. Жунусов, Александр Андреевич Попов, А. В. Нестеров, T. G. Pokrovskaya, Natalia I. Nesterova, Mariia Iu. Goltsova, Alexandra A. Kurbatova, Nikita S. Lyapkalov, Maria S. Sviridova
article en
2 citations

Abstract

Introduction: Neurodegenerative diseases affecting neurons represent a wide spectrum of pathological conditions. To slow the accumulation of pathological tau protein, therapeutic interventions such as a pharmaceutical composition consisting of the tetrapeptide HAEЕ, zinc, and albumin may be employed. This composition possesses properties that can potentially slow disease progression. Materials and Methods: The experiment was performed on 60 homozygous mice of both sexes from a transgenic line with the overexpression of human mutant tau protein (P301S) and on 20 mice from a wild-type C57Bl/6J background line. Control groups (C57Bl/6J – K and P301S – K+) received NaCl injection water (100 µL subcutaneously, once every 2 days); the experimental group (P301S) received HAEE-Zn-HSA (75 mg/kg, 150 µL subcutaneously, once every 2 days); and the comparison group (P301S) received piracetam (1.75 g/kg, 175 µL subcutaneously, once every 2 days). Behavioral activity was analyzed using tests at two time points, and the phenotypic presentation and lifespan were evaluated. Results and Discussion: The P301S group of mice treated with HAEE-Zn-HSA at a dosage of 75 mg/kg showed positive behavioral activity in the following tests: Open Field, Novel Object Recognition, and Inverted grid test, indicating increased exploratory activity, and improved motor function and coordination in the mice of this group. Pharmacological intervention with HAEE-Zn-HSA in the experimental group of transgenic mice demonstrated positive results, as a statistically significant effect on lifespan and delayed onset of the phenotypic presentation of the disease was shown (24±2.14 weeks, p≤0.05). Conclusion: The pharmaceutical composition HAEE-Zn-HSA at a dosage of 75 mg/kg, using a model of homozygous mice from a transgenic line with overexpression of human mutant tau protein P301S, demonstrated high levels of adaptive and exploratory activity and improved motor function.

Research Results in PharmacologyVol. 11(1)
Belgorod National Research University (RU), First Pavlov State Medical University of St. Petersburg (RU), Voronezh State Medical Academy named after N.N. Burdenko (RU)
Openalex Percentile: Top 18%
Chemical Synthesis and Analysis
1.61
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.